BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis - PubMed (original) (raw)
. 2004 Oct 1;64(19):7099-109.
doi: 10.1158/0008-5472.CAN-04-1443.
Christopher Carter, Liya Tang, Dean Wilkie, Angela McNabola, Hong Rong, Charles Chen, Xiaomei Zhang, Patrick Vincent, Mark McHugh, Yichen Cao, Jaleel Shujath, Susan Gawlak, Deepa Eveleigh, Bruce Rowley, Li Liu, Lila Adnane, Mark Lynch, Daniel Auclair, Ian Taylor, Rich Gedrich, Andrei Voznesensky, Bernd Riedl, Leonard E Post, Gideon Bollag, Pamela A Trail
Affiliations
- PMID: 15466206
- DOI: 10.1158/0008-5472.CAN-04-1443
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
Scott M Wilhelm et al. Cancer Res. 2004.
Abstract
The RAS/RAF signaling pathway is an important mediator of tumor cell proliferation and angiogenesis. The novel bi-aryl urea BAY 43-9006 is a potent inhibitor of Raf-1, a member of the RAF/MEK/ERK signaling pathway. Additional characterization showed that BAY 43-9006 suppresses both wild-type and V599E mutant BRAF activity in vitro. In addition, BAY 43-9006 demonstrated significant activity against several receptor tyrosine kinases involved in neovascularization and tumor progression, including vascular endothelial growth factor receptor (VEGFR)-2, VEGFR-3, platelet-derived growth factor receptor beta, Flt-3, and c-KIT. In cellular mechanistic assays, BAY 43-9006 demonstrated inhibition of the mitogen-activated protein kinase pathway in colon, pancreatic, and breast tumor cell lines expressing mutant KRAS or wild-type or mutant BRAF, whereas non-small-cell lung cancer cell lines expressing mutant KRAS were insensitive to inhibition of the mitogen-activated protein kinase pathway by BAY 43-9006. Potent inhibition of VEGFR-2, platelet-derived growth factor receptor beta, and VEGFR-3 cellular receptor autophosphorylation was also observed for BAY 43-9006. Once daily oral dosing of BAY 43-9006 demonstrated broad-spectrum antitumor activity in colon, breast, and non-small-cell lung cancer xenograft models. Immunohistochemistry demonstrated a close association between inhibition of tumor growth and inhibition of the extracellular signal-regulated kinases (ERKs) 1/2 phosphorylation in two of three xenograft models examined, consistent with inhibition of the RAF/MEK/ERK pathway in some but not all models. Additional analyses of microvessel density and microvessel area in the same tumor sections using antimurine CD31 antibodies demonstrated significant inhibition of neovascularization in all three of the xenograft models. These data demonstrate that BAY 43-9006 is a novel dual action RAF kinase and VEGFR inhibitor that targets tumor cell proliferation and tumor angiogenesis.
Comment in
- Revisiting Antiangiogenic Multikinase Inhibitors in the Era of Immune Checkpoint Blockade: The Case of Sorafenib.
Duda DG, Jain RK. Duda DG, et al. Cancer Res. 2022 Oct 17;82(20):3665-3667. doi: 10.1158/0008-5472.CAN-22-2639. Cancer Res. 2022. PMID: 36245248
Similar articles
- Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5.
Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C. Liu L, et al. Cancer Res. 2006 Dec 15;66(24):11851-8. doi: 10.1158/0008-5472.CAN-06-1377. Cancer Res. 2006. PMID: 17178882 - Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L, Trail PA, Taylor I, Wilhelm SM. Adnane L, et al. Methods Enzymol. 2006;407:597-612. doi: 10.1016/S0076-6879(05)07047-3. Methods Enzymol. 2006. PMID: 16757355 - Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D. Strumberg D. Drugs Today (Barc). 2005 Dec;41(12):773-84. doi: 10.1358/dot.2005.41.12.937959. Drugs Today (Barc). 2005. PMID: 16474853 Review. - Sorafenib inhibits growth and mitogen-activated protein kinase signaling in malignant peripheral nerve sheath cells.
Ambrosini G, Cheema HS, Seelman S, Teed A, Sambol EB, Singer S, Schwartz GK. Ambrosini G, et al. Mol Cancer Ther. 2008 Apr;7(4):890-6. doi: 10.1158/1535-7163.MCT-07-0518. Mol Cancer Ther. 2008. PMID: 18413802 Free PMC article. - Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA, Wilhelm S, Carter C, Kelley SL. Gollob JA, et al. Semin Oncol. 2006 Aug;33(4):392-406. doi: 10.1053/j.seminoncol.2006.04.002. Semin Oncol. 2006. PMID: 16890795 Review.
Cited by
- Unveiling therapeutic avenues targeting xCT in head and neck cancer.
Lee J, Roh JL. Lee J, et al. Cell Oncol (Dordr). 2024 Oct 3. doi: 10.1007/s13402-024-00997-9. Online ahead of print. Cell Oncol (Dordr). 2024. PMID: 39361147 Review. - Sorafenib plus memory-like natural killer cell immunochemotherapy boosts treatment response in liver cancer.
Eresen A, Zhang Z, Yu G, Hou Q, Chen Z, Yu Z, Yaghmai V, Zhang Z. Eresen A, et al. BMC Cancer. 2024 Sep 30;24(1):1215. doi: 10.1186/s12885-024-12718-4. BMC Cancer. 2024. PMID: 39350084 Free PMC article. - Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies.
Raghav A, Jeong GB. Raghav A, et al. Int J Mol Sci. 2024 Aug 27;25(17):9286. doi: 10.3390/ijms25179286. Int J Mol Sci. 2024. PMID: 39273237 Free PMC article. - Targeted therapies in hepatocellular carcinoma: past, present, and future.
Gujarathi R, Franses JW, Pillai A, Liao CY. Gujarathi R, et al. Front Oncol. 2024 Aug 29;14:1432423. doi: 10.3389/fonc.2024.1432423. eCollection 2024. Front Oncol. 2024. PMID: 39267840 Free PMC article. Review. - The Role of Bcl-2 Family Proteins and Sorafenib Resistance in Hepatocellular Carcinoma.
de Melo Silva AJ, de Melo Gama JE, de Oliveira SA. de Melo Silva AJ, et al. Int J Cell Biol. 2024 Aug 19;2024:4972523. doi: 10.1155/2024/4972523. eCollection 2024. Int J Cell Biol. 2024. PMID: 39188653 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Molecular Biology Databases
Research Materials
Miscellaneous